Connect with us


Biotech CEO Undergoes Gene Hacking to Reverse Aging



Liz Parrish, CEO of biotech startup BioViva, says she underwent a gene therapy at an undisclosed location overseas last month, a first step in what she says is a plan to develop treatments for ravages of old age like Alzheimer’s and muscle loss, MIT Technology Review reports.

// -- Discuss and ask questions in our community on Workplace.

“I am patient zero,” Parrish said in a Reddit AMA. “I have aging as a disease.” Recognizing aging as a disease that future medicine should be able to cure is an important paradigm shift.

BioViva plans to develop and deliver a suite of therapies each targeting the different consequences of aging and disease and promoting a longer and healthier life. Parrish, who also founded BioTrove Investments, is interested in changing the paradigm of disease and how we view aging and more importantly, how we will treat it moving forward.

// -- Become a yearly Platinum Member and save 69 USD and get access to our secret group on Workplace. Click here to change your current membership -- //

The medical procedure reportedly took place on September 15 in Colombia. Some observers are skeptical, but a filmmaker claims to have filmed the procedure, and hopefully more information and videos will be available soon.

Parrish said that she received injections containing the gene follistatin, which in animal experiments is shown to increase muscle mass, and intravenous dose of viruses containing genetic material to produce telomerase, a protein that extends telomeres, a component of chromosomes known as the “aging clock.” In the Reddit AMA, Parrish said:

It has been over a month and I am sleeping well and have a lot of energy, no other changes reported but we will do blood work soon and I take many pictures.

The Era of Gene Therapy Tourism

The MIT Technology Review article notes that Parrish’s treatment might mark the start of an era in which people receive genetic modifications not just to treat disease, but to reverse aging.

Predictably, the article mentions “ethical” questions about how quickly such treatments should be tested in people and whether they ought to be developed outside the scrutiny of regulators.

Liz Parrish

BioViva CEO Liz Parrish

It appears, however, that Parrish could work around the predictably heavy scrutiny of US regulators by choosing to have her gene hacking sessions done abroad. Therefore, Parrish’s treatment might also mark the start of gene therapy tourism – a form of medical tourism motivated not by cheaper treatments abroad, but by the availability of advanced genetic therapies that are still banned in the home country.

“Gene-therapy preparations, which use a virus to shuttle DNA into human cells, could prove risky,” notes MIT Technology Review. “But the technology has advanced so far in the last decade that it is within reach of a small company.”

Matthew Scholz, CEO of biotech startup Immusoft, imagines that Parrish’s choice might inspire enthusiastic amateurs to try to modify their own DNA, thereby “shifting the balance of power to patients.”

More autonomy and power to patients, often oppressed by the official medical establishment, is urgently needed, and Parrish is to be praised for starting the DIY gene therapy wave by experimenting on herself, like Louis Pasteur did.

“I am happy to be patient zero,” said Parrish in the Reddit AMA. “It is for the world, for the sick children and sick old people.” She added that BioViva is a company that has the mission to get these treatments to those who want it.

Some members of BioViva’s scientific advisory board have criticized Parrish’s decision and distanced themselves. But renowned genetic expert George Church, who is also a BioViva science adviser, is cautiously supportive. He said he didn’t agree with dodging regulators, but added that he found Parrish’s claims plausible.

Images from BioViva and BioTrove Investments.

Important: Never invest money you can't afford to lose. Always do your own research and due diligence before placing a trade. Read our Terms & Conditions here.

Feedback or Requests?



  1. Ira Pastor

    October 19, 2015 at 5:53 pm

    Thisis the beginning of something new that will take on a life of its own
    and most likely result in the emergence of a parallel system of care.

    The convergence of several unique trends, including:

    – personalization of medicine on an “n-of-1” basis,
    – adaptive clinical design,
    – globalization of health care training,
    – compassionate use legislative initiatives for experimental therapies,
    – wider acceptance of complementary medical technologies,
    – the growth of international medical travel,

    the fact that we globally spend $7 trillion annually ($1 trillion spent
    on pharmaceutical products alone, with $200 billion of new R&D) and
    have an absence of curative interventions for any chronic degenerative
    diseases via traditionally regulated channels

    has brought this DIY bio-genie “out of the bottle”

    The “safety argument” has been obliterated by the system’s own actions.

    Today there are literally hundreds of FDA approved products that can:

    – prolong QT and/or Cause Torsades De Pointes resulting in sudden cardiac death;
    – which are IARC Group 1 and 2 carcinogens;
    – which have significant ”black boxed” SAE warnings;
    – not to mention the 2+ million ADEs (100K+
    fatalities annually in U.S. alone) which come from products that have gone through decades of human testing.

    Animal models remain poorly predictive for humans, yet remain a
    mandatory cornerstone behind years and millions of dollars of early drug
    development activities. Penicillin kills guinea pigs and produces birth
    defects in rats, aspirin is poisonous to cats, cancer has been “cured
    in mice” thousands of times, and dozens of drugs found safe in animals
    are later withdrawn from market due to adverse drug events in humans.

    Additionally, we continue to spend billions of dollars on traditional
    “gold standard”, population level clinical studies, despite the fact
    that they use definitions of disease that are excessively inclusive
    (based upon disease characterizations from literally decades ago), while
    at the same time are excessively exclusive of major segments of the
    patient populace.

    What people have begun to understand is that it is pretty much all a big
    gamble, any way you slice it – so why not become an “n-of-1”?

    One only needs to survey the landscape where such dynamics exist in
    “stealth mode” in current society to see where these concepts are
    already permeating our lives.

    From a therapeutic perspective, current FDA initiatives regarding
    expanded access, off-label use, “animal rule only” development, and
    botanical drugs, as well as their public written position on personal
    importation, all highlight examples of various degrees of clinical, “let
    the patient beware” freedom that the agency is quietly willing to grant
    subjects today who seek out such products or who engage in related

    Further afield from pharmaceuticals, markets such as dietary
    supplements, cosmetics, processed ingredient foods/beverages, tobacco,
    legalized marijuana, and pesticide/herbicide usage, all technically
    represent large, uncontrolled clinical experiments on the general
    public, that we all are quite willing to accept today as personal

    It is an interesting new era.

  2. Al Kyda

    October 20, 2015 at 12:40 am

    So who gets to decide who lives forever and who dies? Will wealth be the primary determinant of this?

    I would imagine that most billionaires, being billionaires, wouldn’t mind living forever to enjoy their riches and progress into some sort of a god-like existence as they gain knowledge and experience throughout the eons, and perhaps modify themselves — first genetically, then electronically, finally escaping into the eternal life afforded by a machine substrate for the neurological patterns that comprise them.

    In short, it seems this line of research, if successful, will enable some to become gods, while most will still turn from dust to dust.

    Perhaps this has already happened long, long ago, and we’re living within a superintelligence far beyond comprehension by our primitive wetware?

    • Giulio Prisco

      October 20, 2015 at 7:40 am

      Technologies that people really tend to quickly become cheaper and better due to market pressure. Think of the first mobile phones, big and heavy as bricks and very expensive. Today cell phone companies will give you a much better phone for free when you sign up.

      • FreeJack Furlong

        October 20, 2015 at 8:32 am

        don’t be so naive. your government wants you have a phone so they can track you easily. that’s the only reason they are cheap and plentiful in today’s society.

        • Giulio Prisco

          October 20, 2015 at 8:48 am

          I guess that’s partly true, but there’s no need of conspiracy theories to explain what basic market economics explains perfectly well. If it’s clear that there is money to be made, many players will spend R&D money to improve products and bring production costs down, and the product’s ecosystem will take off. In a few years, the product will be better and cheaper.

          • Zoe D Katze

            December 20, 2015 at 12:41 pm

            The only money she’s received is mine and a penny stock firm and they’re on there way out, closing today at $.0062 per share, in other words they sold $756.00 worth of stock today.

            The symbol is STVA follow them yourself.

            In the past 3 months they’ve dropped from $.30 per share to Friday’s $..0062 with a chart that goes strait down. More importantly they have NO VOLUME 122,000 shares at 6 cents a share is $756.00 of stock sold today. That’s not enough to keep the lights on, but it’s not supposed to it’s just another penny stock scam created to put money in the founders pockets before they drift away. Everyone she’s involved with is a hustler, Stevia the penny stock, Jason Williams the decertified radiologist, Aubrey de Grey who calls himself a Dr but he’s not.


            Don’t say you weren’t warned!

          • P. H. Madore

            December 21, 2015 at 1:21 pm

            It breaks down with some technologies, though, like storage, which can be attributed maybe to collusion between manufacturers.

      • Al Kyda

        October 20, 2015 at 10:33 pm

        Eternal life will likely require technology on a quite different level as compared to smartphones, which advanced simply due to Moore’s Law and routine market forces. It’s more along the lines of space tourism, which only multimillionaires can afford nowadays, but will probably require orders of magnitude more resources and undertaking. Only billionaires might be viable clients at first, and it’s unclear whether the technology would ever become accessible to normal mortals. I wonder whether perhaps the concepts of gods and mortals throughout human history had their roots in a technological singularity long ago, which effectively created the two classes of beings.

  3. advancedatheist

    October 20, 2015 at 12:43 am

    You can mock Miss Parrish now. But wait until she goes into the mountains, creates an ice castle with her superpowers and plunges the world into endless winter.

    • Singhapura

      October 20, 2015 at 5:26 am

      The cold never bothers me anyway

      • advancedatheist

        October 20, 2015 at 5:37 am

        “Let It Go,” the transhumanist grrl power anthem.

  4. Tom K

    October 20, 2015 at 5:09 am

    no hegemony of consciousness…carbon | silicon
    we inhabit time to evolve

  5. Christopher S. Jannette

    October 20, 2015 at 7:05 am

    Give her the Nobel Prize for Medicine!!!!

  6. Brad Arnold

    October 20, 2015 at 7:18 am

    Let me refer to BioViva’s ethics page: ( ):

    “BioViva believes everyone should have access to cutting-edge medical treatments, not just those who can afford it. New technologies rapidly become accessible to consumers, now more than ever…To hasten this process we intend to construct a manufacturing facility to significantly reduce the cost of our gene therapies. We have invested in mass production technologies such as bioreactors in order to produce more vectors reduce the final price for the consumer. We will continue to seek more efficient methods in our constant search to bring access to everyone.”

    • Zoe D Katze

      December 20, 2015 at 12:23 pm

      If that’s truly the case, why is she partnered with a penny stock firm and hustling men out of their money? With no background in Medicine, biology, chemistry and her only background in lying and hustling I can tell you that a few months after a her procedure where she was treated outside the US by a Radiologist who was de-certified and sanctioned by the FDA, she is already looking much worse in a mere 90 days. Since we know these injections cause cancer in both in Vico and in vitro I’m concerned she’s already showing the signs. There’s a reason while clinical trials are done in 3 stages and take extended time. If you want to see what she looked like prior to the zColombian procedure, there will soon be a series of websites scientifically refuting her entire scam. One at another at She’s soooo intelligent she didn’t even buy who own domain. My guess is because this entire thing is a scam so why would she want the world seeing her name. Only those stupid enough to be hustled out of their money by her, embarrassingly, me included

      • Brad Arnold

        December 20, 2015 at 5:21 pm

        I am so surprised by your take on this. Since I have dealt in other somewhat unorthodox, but third party verified, technologies, I’ve ran into a few individuals that simply believe that they are fraudulent and lead crusades against them for (what appears to outside observers as) idiosyncratic reasons bordering on zenophobic. Since this is the first time I’ve had exposure to your viewpoint, I can’t say, but needless to say I will be keeping a close eye on you to see if you are on the level or just expressing hatred and undue skepticism resulting in defamation rather than true information.

  7. FreeJack Furlong

    October 20, 2015 at 8:30 am

    good luck. i heard all the useless trust fund babies on this planet are fairly high on the grim reaper’s list.

  8. Zoe D Katze

    December 20, 2015 at 12:11 pm

    Bioviva I

    I first met Liz Parrish Founder and President of Bioviva Sciences on in 2012, 2 years after my wife of 34 years died from Lymphoma, I was her perfect mark. Lonely, depressed, and wealthy. She began by sending me a partially nude photo (anyone is welcome to see), it will soon be posted along with further detailed information on a new website, The domain which I purchased yesterday is After receiving the photo came lie number one, where she said that she was unmarried. When I had a private investigator do a full background check, that turned out to be a untrue. When I confronted her with the FACTS, she made up lie number two, saying she was separated. When I confronted her again with the Private Investigators proof she was indeed married and living with her husband, Chris, next came lie number three, i.e., that they lived in separate bedrooms on opposite sides of their home “for their children’s sake.” The lies continued, but the bottom line is she made 5 trips from Seattle to San Francisco, LA, Miami and elsewhere with me, all first class, each time staying in 5 star hotels, all on my dime, and of course all the while trying to hustle me for money. My opinion, her and her companie(s) (note I say companies because in year 1 she was BioTrove Investments, by year 2 she’s now Bioviva. What will next year bring?, my vote is on BioScam). I have emails and texts from her saying how special I am to her, etc., etc. But as soon as I cut the money off, she was gone. Personally I’ve had an amazing life and have no desire to live forever. I consider that to be hubris at its strongest. The fact is the most advanced work in this area is being done by MIT’s Dr. Lenny Guarente, one of the world’s leading scientists in the field of aging research. He’s being advised by five Nobel Prize winners and two dozen other top researchers in this field. I don’t see ANY Nobel Prize Winners on BioTrove or BioViva’s or BioLiz’s board, just a long list of quacks and de-certified M.D.’s like Jason Williams, who was a Dr. in the US, but not specializing in biology or chemistry, he was a Radiologist, and not much of one as you can read here,…/precision-stemce…/

    If you’re truly interested in the cutting edge work in this field, try reading this…/one-of-the-worlds-top-aging-re… In my opinion she’s a scammer and I believe the reason she will not release any further information is we will find the entire fiasco was financed by others just like me. Just look at the Dr. who oversaw the procedure, it’s our old pal Jason Williams, he with the degree in Radiology. When the FDA shut him down, he moved to Colombia. The one thing I will agree with is Liz Parish is a very attractive woman, making her very persuasive when she wants to be. Don’t they have a name for excepting money whilst using your good looks? She has NO advanced degree in science whatsoever, no MD, no PhD, no degrees in biology or chemistry, shes not even an LPN. Beyond that, when I went out of my way using long cultivated contacts to get her into UC Irvine’s Stem Cell Laboratory for a private tour and meeting she embarassed me by scoffing at pluripotent stem cell research and therapy. I had a meeting with Craig Venter arranged also, but when I was able to use my contacts to get her a meeting with stem cell pioneer Neurobiologist Dr. Hans Kierstaad, she scoffed at his work too.…/124-million-… Between this, my lost money and the fear of further embarrassment in front of Venter, I decided to cut her off after one more try. I flew her from Seatle to San Francisco to Florida and back, first class of course, put her up in yet another 5 star hotel and when she told me she was going shopping for the day before catching a flight home, I discovered she never caught her plane, but instead she went to the life extension offices in Boca Raton. At this point, this being a $10,000.00 trip I sent her packing for good. Funny thing, since the money stopped and the access to the REAL scientists stopped, she’s now refused to return an e-mail in order to have an intelligent discussion or debate on the topic, which as we all know is a major part of the protocol in breaking through to new technologies. Apparently Dr Parrish, excuse me, Nurse Parrish, whoops wrong again, Sugarbabby Parrish disagrees. Interviewed numerous times about her home and family have you noticed SugarBaby Liz still refuses to answer if she is married. She immediately removed ALL the pictures and references to Chris and her two children from her Facebook page. IMHO this is a scam, all about money. Who would you trust, a Dr. Whose worked at MIT in this field for 34 years, or someone with NO advanced degree in any form of medicine, biology, chemistry, or for that matter NO experience in ANY research in any field. Don’t say you weren’t warned. The procedure performed on Ms. Parrish in Colombia is known to cause cancer in mice, imagine what it will do in humans? Here are but 2 of 8,000 results confirming the danger of this scam found on a PubMed search.

You must be logged in to post a comment Login

Leave a Reply


Biotech Dominates July Penny Stock Picks



July brings new opportunities to trade penny stocks, according to the Investopedia top 10 penny stocks to watch. Biotechnology stocks in particular are poised for a breakout. Biotechnology funds broke out of the long-term basing pattern in June, forcing rotational buying pressure, which bodes well for the low-priced sub-sector, with many penny stocks ready to hit multi-year highs.

// -- Discuss and ask questions in our community on Workplace.

At the same time, the tech sector is getting sold with equal force in a profit-taking exercise that could deliver a period of under-performance for the sector’s lower-priced issues.

June’s biotechnology picks drew strong buying interest, led by ImmunoGen, Inc.’s 48% advance to a 52-week high. Small China stocks also posted strength, as China Commercial Credit, Inc. gained close to 35%. China Commercial Credit and June’s three biotech picks return to the July top penny stock list, joined by six new penny stocks.

1. ImmunoGen Inc. (IMGN)

Source: Investopedia

// -- Become a yearly Platinum Member and save 69 USD and get access to our secret group on Workplace. Click here to change your current membership -- //

ImmunoGen, a provider of antibody-drug conjugates (ADCs) for the treatment of cancer, jumped from number four in June to the top spot in July.

The stock posted a 12-year high at $20.25 in 2013 and sold off to $5.34 in December 2014. A recovery in 2015 stalled less than a point below the prior peak, creating a decline that continued into an 18-year low at $1.51 in November 2016.

Buyers took over in 2017, generating an uptick that reversed at the 2014 resistance approximately three weeks ago. In June, the stock broke out and made the top 10 list for the first time. It could end up in the $8.00 to $10.00 price zone.

ImmunoGen creates targeted cancer therapeutics using its proprietary ADC technology. The company’s candidate, mirvetuximab soravtansine, is in a Phase 3 trial for an ovarian cancer, and is in Phase 1b/2 testing in combination regimens for earlier-stage disease.

The technology is used in Roche’s Kadcyla, in three other clinical-stage ImmunoGen product candidates, and in programs in development by Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda.

2. China Commercial Credit, Inc. (CCCR)

Source: Investopedia

China Commercial Credit Inc. (CCCR), which provides business loans and loan guarantee services to small-to-medium enterprises (SMEs), farmers and individuals in China’s Jiangsu Province, jumped from number five in June to second place in July.

The company went public on the U.S. exchanges at $6.50 in August 2013.

The stock experienced a downtrend that bottomed out at 25 cents in February 2016 and began an upward trend that stalled at $3.20 in September. The stock hit a higher low in March 2017 before recovering, testing the 2016 high. A breakout should bring broad buying interest that could support a continued upside that could double the price by year’s end.

The company was founded in 2008 and provides business loans and loan guarantee services to small-to-medium enterprises, farmers and individuals in China’s Jiangsu Province.

3. CymaBay Therapeutics, Inc. (CBAY)

Source: Investopedia

CymaBay Therapeutics Inc. (CBAY), a clinical-stage biopharmaceutical company developing therapies to treat specialty and orphan diseases, returns from the June list, where it ranked number 9. The stock rallied to an all-time high at $13.78 in February 2015, then suffered a steep downtrend that continued into the first quarter of 2016. The stock then dropped to an all-time low at 82 cents before bouncing to $3.04 in April, a yearly high, ahead of a pullback that continued into the November low at $1.15.

The stock broke above the 2016 high in February 2017, reaching a two-year high at $4.81.

Net loss for the 2017 first quarter was $5.4 million, or ($0.20) per diluted share, compared to $6.8 million, or ($0.29) per diluted share in the first quarter of 2016. Net loss in the 2017 first quarter was $1.4 million lower compared to the prior year period, primarily due to the recognition of collaboration revenue in 2017.

The rally has now reached a two-year high, attracting buying interest that could move into double digits.

4. Peiris Pharmaceuticals, Inc. (PIRS)

Source: Investopedia

Pieris Pharmaceuticals Inc., a, clinical-stage biotechnology company committed to providing solutions for oncology, respiratory disease and other therapeutic areas, moved from June’s 7th spot to July’s 4th spot. The stock launched on the OTC market in 2014, trading between $2.00 and $4.25 before falling to $1.26 in January 2016. It ground sideways through November, then tested the first-quarter low ahead of a January 2017 breakaway gap that has drawn steady buying interest. The rally gathered momentum in early May after announcing a partnership with AstraZeneca PLC and is currently testing the 2015 high, the all-time high.

The company’s product includes immuno-oncology multi-specifics tailored for the tumor microenvironment, an inhaled Anticalin protein to treat uncontrolled asthma as well as a half-life-optimized Anticalin protein to treat anemia. Anticalin proteins, proprietary to Pieris, are a class of therapeutics validated in the clinic and partnerships with pharmaceutical companies. Anticalin is a registered trademark of Pieris.

5. 22nd Century Group, Inc. (XXII)

Source: Investopedia

22nd Century Group, Inc. (XXII), a plant biotechnology company that is a provider of tobacco harm reduction and development of proprietary hemp/cannabis strains, broke out above multi-year resistance near $1.50 in 2013, rallying to a record high a few months later at $6.36. The stock then began a persistent decline through August 2015 before finding support at 56 cents, followed by a bounce to $1.75.

The stock has traded within those boundaries for 22-months, bouncing at support three times and reversing at resistance in equal measure. The price returned to that level a fourth time, improving odds for a breakout that could double the price in the year’s second half.

22nd Century Group is a plant biotechnology company focused on genetic engineering and plant breeding that allows the increase or decrease of the level of nicotine in tobacco plants and the level of cannabinoids in cannabis plants. The company’s main goal in tobacco is to reduce the harm caused by smoking. The main goal in cannabis is to develop proprietary hemp/cannabis strains for new medicines and agricultural crops.

The stock last month joined the Russell Microcap Index, when FTSE Russell reconstituted its U.S. and global equity indexes. Membership in the Russell Microcap Index means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

6. Corindus Vascular Robotics, Inc. (CVRS)

Source: Investopedia

Corindus Vascular Robotics, Inc. (CVRS), a developer of precision vascular robotics, returned to the national market in 2015 following a trading halt, topping out around $4.50 and starting a decline that continued to reach new lows in January 2017 when it bottomed at around 40 cents. Since that time, the price activity has been constructive, with high volume rally bursts moving the stock into 2016 resistance at $1.75. The bullish behavior has created a cup and handle basing pattern that points to an uptrend into the 2015 high following a breakout.

Revenue for the first quarter of 2017 was $0.8 million compared to $1.1 million for the same period in the prior year. The decrease is due mainly to the deferral of system revenue associated with a future obligation to upgrade multiple customer units from the company’s CorPath 200 System to the CorPath GRX System.

The company installed three new CorPath Systems in the first quarter of 2017, increasing its total installed base to 48 CorPath Systems.

Gross loss was $1.1 million for the 2017 first quarter, compared to a gross profit of $0.03 million for the 2016 first quarter. The cost of revenues for the first 2017 quarter continued to include the effect of under-utilization of production facilities and the cost of CorPath GRX System upgrades that installed pursuant to pre-existing contractual arrangements.

The company continues to expect the full year 2017 revenue to be in the range of $13.

7. RADA Electronic Industries, Ltd. (RADA)

Source: Investopedia

RADA Electronic Industries, Ltd. (RADA), a defense electronics system of advanced electronic systems for airborne and land applications, fell into a multi-decade decline after it joined the Nasdaq in the 1990s. The stock ground out a series of lower highs and lows through January 2016’s all-time 54-cent low.

The stock spent 16 months moving sideways in a narrow basing pattern before turning higher in May 2017 and rallying back to 2016 resistance at $1.78. The bullish activity completed a cup and handle breakout pattern that could point to a fast rally into the August 2015 gap between $3.70 and $2.50.

Revenues totaled $4.7 million in the 2017 first quarter, up 91% compared to revenues of $2.5 million in the first quarter of 2016.

Gross profit totaled $1.7 million in the first 2017 quarter of 2017, a gross margin of 35.7%, compared to gross profit of $6,000 (gross margin of 0.2%) in the 2016 first quarter.

Operating income was $0.4 million in the first 2017 quarter compared to an operating loss of $1 million in the 2016 first quarter.

Net income attributable to RADA’s shareholders in the 2017 first quarter was $0.4 million, $0.02 per share, versus a net loss of $1.8 million, or $0.23 per share, in the 2016 first quarter.

8. ChromaDex, Corp. (CDXC)

Source: Investopedia

ChromaDex, Corp. (CDXC), a provider of proprietary health, wellness and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition and pharmaceutical products, went public in April 2016 at $4.70. The stock rallied to an all-time high at $6.18 in May, then fell one month later to $2.46 in a single session, eventually posting a lower December low. It tested that support level in April 2017, then turned sharply higher, now testing 2017 resistance at $3.80. A breakout could point to a significant upside, taking the stock back to last year’s high.

For the first quarter of 2017, ChromaDex reported net sales of $4.4 million, a decrease of 39% compared to the same period of 2016, due mainly to decreased sales in its ingredients business segment, as a result of dropping its largest customer for fiscal year 2016. The ingredients segment created net sales of $2.1 million for Q1 2017, a decline of 55%, compared to the same 2016 period.

The net loss attributable to common stock holders for Q1 2017 was $1.9 million or ($0.05) per share versus a net income of $0.3 million or $0.01 per share for Q1 2016.

In May, the company announced the closing of the $16.4 million second tranche of the strategic investment of up to $25 million led by Hong Kong business leader Li Ka-shing.

Li Ka-shing has invested in many innovative companies in the last decade, including Facebook, Spotify, DeepMind, Siri, Impossible Foods and Modern Meadow. The new investment will support future ChromaDex developments in the global marketplace.

The $16.4 million second tranche follows an initial $3.5 million tranche that closed on April 27, 2017.

9. Safe Bulkers, Inc. (SB)

Source: Investopedia

Safe Bulkers, Inc. (SB), a player in the hot and cold dry bulk shipping sector, topped out at $11.48 in March 2014, then entered a downtrend reaching an all-time low at 30 cents in January 2016. A recovery wave in November stalled at $2.38, followed by sideways action that has completed a small-scale cup and handle breakout pattern. A buying spike over $2.60 can be expected to set the upside into action, supporting a rally that could surpass $5.00.

The company declared a cash dividend of $0.50 per share on its 8.00% Series B, Series C and Series D Cumulative Redeemable Perpetual Preferred Shares for the period from April 30, 2017 to July 29, 2017.

This is the 16th consecutive cash dividend declared on the company’s Series B Preferred Shares, the 13th cash dividend declared on its Series C Preferred Shares and the 12th cash dividend declared on its Series D Preferred Shares since their respective commencement of trading on the New York Stock Exchange.

10. Ballard Power Systems, Inc. (BLDP)

Source: Investopedia

Ballard Power Systems, Inc. (BLDP) is a provider of clean energy products that reduce customer costs and risks, and helps customers solve challenges in their fuel cell programs. The stock reached an all-time high at $144.95 in 2000 before falling into a downtrend lasting more than 12 years, sending the stock to an all-time low at 56 cents. A 2013 upward trend continued through 2014, hitting an 8-year high at $8.38, followed by a correction that’s now returned to 2015 resistance at $3.10. A breakout could catch fire, pushing the stock to a test of its 2014 high.

Total revenue was $22.7 million in the quarter, an increase of 39% from growth in both power products and technology solutions.

Gross margin was 42% in the quarter, an improvement of 22 points due to a shift in product mix toward higher margin technology solutions and heavy duty motive for the China market, including the establishment of a production line in Yunfu, China for the manufacture and assembly of FCvelocity-9SSL fuel cell stacks.

Cash operating costs were $10 million in the quarter, a 6% increase due to higher research and product development expenditures as well as a stronger Canadian dollar relative to the U.S. dollar, since a significant amount of cost is denominated in Canadian dollars.

Low-priced biotech stocks have risen following a long slumber, with steady buying interest likely to continue. This group should offer a variety of profitable penny stock plays during the quiet summer trading season, while low-priced stocks in other sectors move into narrow trading ranges.

Featured image from Shutterstock.

Important: Never invest money you can't afford to lose. Always do your own research and due diligence before placing a trade. Read our Terms & Conditions here.

Feedback or Requests?

Continue Reading


Silicon Valley’s War on Disease: Zuckerberg, Microsoft, Google to End Cancer and Aging



Chan Zuckerberg Initiative

Silicon Valley is going to war against disease, cancer, aging, and perhaps even death, with advanced computing, AI and machine learning, genomics, DNA engineering, biotech and nanotech. Tech giants and mega-rich philanthropists are spending billions to permit hacking biology all the way down to DNA, and perhaps we could see breakthroughs in only a few years.

// -- Discuss and ask questions in our community on Workplace.


Important: Never invest money you can't afford to lose. Always do your own research and due diligence before placing a trade. Read our Terms & Conditions here.

Feedback or Requests?

Continue Reading


Child With Rare Disorder Receives ‘Bionic’ Hand Made By 3D-Printer



A prosthetic hand made with 3D-printing technology has provided a functional right hand for a 6-year-old boy born with a rare disorder, according to Reuters. The boy, Lucas Abraham, showed his new “bionic” hand made for him by bioengineering students at the University of Louisville in Louisville, Ky.

// -- Discuss and ask questions in our community on Workplace.

The child noted that it’s the best Christmas gift he’s ever received during a news conference at the university. Within minutes of receiving the hand, Abraham could grasp a ball. A video posted on Twitter shows Lucas getting some practice playing catch with a ball using his new hand. The boy will also be able to crash cymbals together in his music class.

Child Had Asked For A ‘Robo-Hand’

Abraham was born with Symbrachydactyly, a condition where a person does not have a fully-functioning hand or foot. The child was born without fingers on his right hand.

// -- Become a yearly Platinum Member and save 69 USD and get access to our secret group on Workplace. Click here to change your current membership -- //

He had asked for a “robo-hand” for years, a prosthetic device that would allow him to hold a piece of paper, grab a baseball and help him zip his jacket, according to the Courier Journal in Louisville.

Following months of work by the students, this week Abraham went to his school, Bowen Elementary School, wearing his “bionic” hand. The device uses tendon-like cords that allow the child to grip when bending his wrist.

The hand was the first made at the university, according to bioengineering professor Gina Bertocci, who noted that more such hands could be made. The university described the hand as “bionic.”

The 3D technology reduces the manufacturing cost. The plastics used, similar to Lego blocks plastics, enable the devices to be made in different colors, Bertocci noted.

Also read: Interview: The makers of a robotic hand that can ‘feel’

3D Printing Creates New Opportunities

3D printing made it possible to make the hands for less than $50 in materials versus thousands that would be required to make a traditional prosthetic hand, according to Bertocci.

The students created a digital version of the hand and used a 3D printer the size of a small refrigerator to ensure the hand was the right fit. It took more than 30 hours to print each hand.

Kids like the hand because it makes them look like a Transformer, Bertocci added.

e-NABLE, a global volunteer organization that prints and designs prosthetics, provided assistance to the students.

Three hands made of leather, plastic and wire were created to fit Abraham, who will keep two of them while the university will use the third hand for accreditation purposes.

The hands were given to the Abraham family for free.

Julie Abraham, the child’s grandmother, said he has displayed more self-confidence after receiving the hand. She had contacted the university in August to see if they could help him.

Image credit:

Important: Never invest money you can't afford to lose. Always do your own research and due diligence before placing a trade. Read our Terms & Conditions here.

Feedback or Requests?

Continue Reading